Harvard Bioscience
HBIO
95 hedge funds and large institutions have $65.5M invested in Harvard Bioscience in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 35 increasing their positions, 25 reducing their positions, and 14 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 25
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
1% more funds holding
Funds holding: 94 → 95 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.06% less ownership
Funds ownership: 7.17% → 7.12% (-0.06%)
22% less capital invested
Capital invested by funds: $84.2M → $65.5M (-$18.7M)
96% less call options, than puts
Call options by funds: $2K | Put options by funds: $51K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$1.18M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$288K |
| 3 |
Morgan Stanley
New York
|
+$271K |
| 4 |
AE
AMH Equity
Great Neck,
New York
|
+$255K |
| 5 |
WN
Williams & Novak
Westlake Village,
California
|
+$228K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$685K |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$570K |
| 3 |
2C
272 Capital
Dallas,
Texas
|
-$424K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$424K |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$346K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
101
Landscape Capital Management
Englewood,
New Jersey
| – | -$49.5K | -1,840 | Closed |
|
|
PCM
102
Prelude Capital Management
New York
| – | -$35.3K | -1,311 | Closed |
|
103
Millennium Management
New York
| – | -$32.2K | -1,195 | Closed |
|
104
Allspring Global Investments
Charlotte,
North Carolina
| – | -$3.89K | -145 | Closed |
|
105
Osaic Holdings
Scottsdale,
Arizona
| – | -$3.28K | -122 | Closed |
|
|
CWP
106
Concord Wealth Partners
Abingdon,
Virginia
| – | -$2.02K | -75 | Closed |
|
|
BTI
107
Blue Trust Inc
Alpharetta,
Georgia
| – | -$222 | -8 | Closed |
|
|
CPA
108
Capital Performance Advisors
Walnut Creek,
California
| – | -$110 | -4 | Closed |
|
HBIO Hedge Fund Activity: Q4 2024 in Review
95 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q4 2024, worth a combined $65.5M — down 22% from $84.2M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new HBIO positions and 14 closed out — a net gain of 2 holders — while 35 added to existing stakes and 25 trimmed.
The largest buyer was Royce & Associates, adding an estimated $1.18M. The largest seller was Russell Investments Group, cutting an estimated $685K.
- 95 institutional investors held Harvard Bioscience (HBIO) as of Q4 2024, up from 94 in Q3 2024.
- Funds reported $65.5M of Harvard Bioscience stock for Q4 2024, down 22% quarter-over-quarter.
- 16 funds opened new Harvard Bioscience positions in Q4 2024 and 14 closed out, a net change of +2 holders.
- The largest Harvard Bioscience buyer in Q4 2024 was Royce & Associates, an estimated $1.18M added.
- The largest Harvard Bioscience seller in Q4 2024 was Russell Investments Group, an estimated $685K sold.
Based on aggregated 13F filings for Q4 2024.